• Renalytix to Present at 42nd Annual William Blair Growth Stock Conference

    Source: Nasdaq GlobeNewswire / 08 Jun 2022 07:00:00   America/New_York

    NEW YORK and SALT LAKE CITY, June 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42nd Annual William Blair Growth Stock Conference on Thursday, June 9 at 2:00 p.m. CT. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at investors.renalytix.com. 

    For further information, please contact:

    Renalytix plcwww.renalytix.com 
    James McCullough, CEOVia Walbrook PR 
       
    Stifel (Nominated Adviser, Joint Broker)Tel: 020 7710 7600 
    Alex Price / Nicholas Moore  
       
    Investec Bank plc (Joint Broker)Tel: 020 7597 4000 
    Gary Clarence / Daniel Adams  
       
    Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com 
    Paul McManus / Lianne Applegarth / Alice Woodings Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 
       
    CapComm PartnersTel: 415-389-6400 or investors@renalytix.com 
    Peter DeNardo   

    About Renalytix 
    Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosisTM for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory-developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D with early CKD stages 1-3. We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.


    Primary Logo

Share on,